02/12/2021

10:30:00 pm
2021 GN - My message to the world at COP26 (gates).pdf


Keypoints

  • COP 26, net zero 2050 (Glasgow, Scotland)
  • poorest people contribute least to climate change
  • CATALYST effort: 4 goals, 1. tech expertise 2. link gov resources w_business exp. 3. Phylantropic grants + equity, w_low return expec 4. certainty of costumers

2021 CNBC - U.S. officials keep close watch on the ‘delta plus’ Covid mutation as it spreads in the U.K..pdf

Keypoints

  • AT.4.2 delta plus
  • 10-15% ‘>contag’ DELTA
  • Balloix, Genetics Inst. London: easier spread than Ebola, SARS, MERS & 1918 Spanish flu
  • Delta = R8-9 / original (wild-type) = R3
  • CDC: no evidence of ∆plus impact on effectiveness of vax or tto.”

CCH, JCAS, AAQC

01/12/2021

10:30:00 pm

2021, BBVA - La neurociencia de las emociones (Rojas-Estapé) [vid]

2021 MEDPAGE - Should I Get My COVID Booster (Fiore) [NEJM].pdf

Brief

  • Nov 24, thankgiving
  • GMT: Geometric Mean Titers
  • Pfizer ok, NEJM, 20 up. • Wild-type disease: basis, no mutation • 2021, NEJM, IL - obs, 1.1M, 1m (Jul-Aug) - >60, boost, not-boost, low INF & sILL (Oct 7) • 2021 LANCET, IL - obs, 728k, x - 52yo, boost, no-boost, 93%;92%;81% admiss, severe, MM... efficacy preventing

GSQA, AAQC

30/11/2021

10:30:00 pm

2021 Surviving Sepsis Campaign - Vasoactive Agent Management [Imagen]

2021 WHO - WHO’s Science in 5 on C-19. Mixed + fractional vaccine doses [News]

Keypoints

  • GI distress y ataxia
  • Twice per week (one in BO)
  • Harmful

AAQC

29/11/2021

10:30:00 pm

2021 MEDPAGE - Ivermectin for COVID-19 Linked to Severe Toxicity in Small Study (NEJM)

2021 NEJM - Toxic effects from ivecmectin use associated with PREV + TTO of C19 (temple) [corr]

Brief

  • JYC: NEJM, 2021, USA
  • DPT: Call reports, 21, August
  • P: C19 prev & tto
  • I: different dosis (med and vet)
  • C: no
  • O: adverse reactions reported

CCH, AAQC

December, 2021
November, 2021

03/12/2021 

10:30:00 pm (CEST) 

2021 AJTMH - Pragmatic Recommendations for Therapeutics of H C19 pxs in LMIC (shetty) [r]

2021 LANCET - RECOVERY (Horby) [RCT].pdf

2021 NEJM - REMAP-CAP (Gordon) [RCT]

NEJM 2021 - EMPACTA (Salama) [RCT]


Keypoints

  • LMIC: changed since pub Aug28,2021
  • RECOVERY: LANCET, 2021, UK ➩ RCT / 4116 / Apr23,20_Jan24,21 ➩ P SpO2<92%_crp≥75mg/L, I toci 400-800mg ±2nd dose C placebo, O (p) ↓MM28 (s) ↓ttHd, ↓iMV_or_MM
  • REMAP-CAP: NEJM, 2021, UK ➩ RCT / 353 / p:Feb25,21 ➩ P ICUpxs d_24h w_∆sup(hfnc ->) OR ♡sup(vp), I toci 8mg/Kg (800mg tops) OR sari 400mg, C no both, O (p) ↓ ∆♡supp fD + f_organ supp D21
  • EMPACTA: NEJM, 2020, USA ➩ dbRCT / 340 / May14.20_Sep30,20 ➩ P SpO2<94 + FiO2 0.21, I toci 8mg/Kg (max 800mg) 1or2doses, C placebo, O (p) ↓ MV_or_MM28 (s) = ttHd_or_readyForHd D28


ALAC, JCAS, CCH, K, R, AAQC

04/12/2021

10:30:00 pm (CEST)

2021 ICM - Dexamethasone 12 mg vs 6 mg for pxs w_COVID-19 + severe hypoxaemia (Granholm) [R] .pdf





Keypoints

  • ICM, 2021, DK, IN, SWE, ZWIT ➩ anal Bayes / >950 / Ago20_May21 ➩ P c19 + hypoSev , I dexa12 , C dexa 6 , O (p) Dalive wo_lS 28 (s) Dalive wo_lS 90 + Dalive ooH 90
  • COVID STEROID 2: O (s) + MM28, MM90, AR28

CCH, JCAS, GSQA, AAQC

06/12/2021 

10:30:00 pm (CEST) 

2021 UNIVADIS - IDWeek 2021 Antibody cocktail effective at preventing symptomatic C-19 (IDWeek 2021 - PROVENT).pdf


ID WEEK CONF (PROVENT), 2021, USA ➩ db.mc.RCT + >5100 + ? ➩ P wo_priorC19, unvax I AZD7442 = tixagevimab + cilgavimab (150mg each), C placebo, O (p) 1st case C19 SYMPT after AZD7442 / ↓77% RR (s) AE= + INJECsite=



AAH, AAQC

07/12/2021 

10:30:00 pm (CEST) 

2021 MEDS - COVID-19/ early awake prone positioning linked to lower mortality (Blair).pdf


Brief

  • CC, 2021, USA ➩ obs / >120 / ? ➩ P within 24h of HFNC I awake proning early [2h] C late [36h] O (p) MM / 26 vs 45% (p=0.039) (s) INTUB OR lCU/H LOS ➩ mvA: MMpredict older, iMV, longerDELAY, hydro.

AAQC

13/12/2021 

10:30:00 pm (CEST) 

2021 NEJMjw - Bacterial Superinfection Is Found in a Minority of Patients Admitted with COVID-19 Respiratory Failure (AJRCCM).pdf


Brief

  • BLUE, 2021, USA ➩ intervent PROS / 179 / 4m ➩ *P* C19, sARF, ICU *I* bal + BAL addition if VAP *C* none *O* MM=.

2021 NEJMjw - Does a Higher Dose of Dexamethasone Improve Clinical Outcomes in pxs w_Severe COVID-19 (JAMA).pdf


Keypoints

  • JAMA 2021 (COVID STEROID 2)
  • 1000, 12vs6 x 10
  • woLifeSuppp =, MM28 =, AR = (infections)
  • underpowered
  • toci + baricitinib

PICL, AAQC

15/12/2021 

10:30:00 pm (CEST) 

2021 MEDPAGE - Doctor Sues Hospital Over Ivermectin Ban Amid Journal Article Retraction



Keypoints

  1. JICM retracted math+
  2. CONCERNS of the accuracy of MM data reported in Norolk Gral Hosp.
  3. Lawsuit ongoing
  4. CDC, NIH, FDA do not recommend ivermectin for C19

MKFA, AAQC

22/12/2021 

10:30:00 pm (CEST) 

2021 ICM - Randomised clinical trials in critical care. past, present + future (Granholm) [r]


Keypoints

  1. ICM, 2021, DK
  2. hypothesis gener VS pract chang
  3. perspectives, hopes and realities
  4. Primary challenges of conventional RCTs

MKFA, CCH, JJFM, AAQC

23/12/2021 

10:30:00 pm (CEST) 

2021 ICM - Randomised clinical trials in critical care. past, present + future (Granholm) [r] .pdf

Limitations

  1. effect sized in ClinPract decision
  2. NIH GL (ivermec): size, design, conduct…

2021 NEJMjw - Is Measuring D-Dimer Helpful in Hospitalized C19 pxs w_Suspected PE (JAMA).pdf

  1. JAMA, 2021, Florida ➩ retro / 1500 / Jan 2020 - Feb 2021 ➩ *P* C19 pxs *I* D-dimer + CTPA *C* NO *O*:
    - PE(+): D-dimer ↑↑↑ (>500 ng/mL) + CTPA (+)
    - PE(-): D-dimer ↑ + CTPA (-)
  2. NegPredVal is 100% with D-dimer
  3. Pxs w_C19 and ↑D-dimer could have PE

PICL, MKFA, CCH, GSQA, AAQC

30/12/2021 

10:30:00 pm (CEST) 

2021 NEJMjw - Use Of Medications That Might Raise Blood Pressure (JAMA).pdf


JAMA, 2021, USA ➩ OBS / 28mil / 10 años ➩ *P* HTA *I* med ↑TA (self-reported + >130/80) *C* no *O* 19% HTA were using med↑TA


Antidepress, NSAIDs, corticosteroids, estrogens, stimulants (GL 2017)

2021 HEALIO - Monoclonal antibody combination reduces COVID-19 hospitalizations, deaths by nearly 80%.pdf


X, 2021?, 6countries (USA, BR, MX, ARG, PHI, SudAfri) ➩ RCT / <840 / 7m (2021) ➩ *P* 10d symp COVID + hRClinProg *I* Amubarvimab/Romlusevimab (BRII-196/BRII-198)*C* placebo *O* combined EP (hosp + MM) ↓80%

PICL, MKFA, AAH, AAQC

1. A JR is an academic session where we go through some articles previously codified/labelled, for 45 -60min.
2. It takes place every day, except Sundays and the very last day of the month.
3. Its purpose is to understand and discuss relevant elements of the content by taking interactive and pedagogic notes (systematized note-taking methodologies) about the content.
4. We generate discussion and recall pivotal concepts about different topics, all pertinent to our clinical practice.

5. We write down the key -points of every session and publish them on our website

6. In the following session we apply the 'reinforcing rule' by recalling the key-points from the previous JR day and/or the past homonymous weekday.

7. The articles for the week are posted in advance in the jr-info-ⓘ channel of the Journal Reviews (JR) category of our DISCORD server.

Journal Reviews

Notes to navigation

  • PICO: Population/problem, Intervention, Comparison, and Outcome;
  • RCT: Randomized Controlled Trial; dbRCT: double blinded RCT;
  • TTO: Treatment;
  • ♡sup(vp): Cardiac Support (Vasopressors);
  • ∆sup: Respiratory Support;